Search bioRxiv⌕ Search

Biology subjects

Leser, F.

Publications and source records attributed to Leser, F..

2 recordsLinked to original sources

The Nuclear-Cytoskeletal Interface Is a Vulnerability in Aging Endothelium

Vascular aging is a fundamental driver of age-related cardiovascular diseases. Endothelial cells (ECs) lining the vascular lumen of capillaries are specialized, thin cells that supply tissues with metabolites, and their loss in aging poses a threat to tissue perfusion and ischemia risk. Mechanisms causing capillary dropout in aging are largely unknown, although VEGF signaling deficiency is implicated.15 To identify mechanisms involved in vascular aging, we investigated mice with the accelerated aging disorder Progeria, and aged wildtype mice. At the organismal level, Progerin expression reduced sprouting angiogenesis and capillary density in neonatal mouse retinas, which impaired tissue perfusion and increased DNA damage compared to wildtype littermates. Progeric capillaries and aortic ECs displayed a disrupted nuclear-cytoskeletal interface that was shared with aged wildtype mice. 4D EC sprouts derived from Progeria mice had mispositioned nuclei at sprouting tips and bulging nuclei that failed to flatten and obstructed lumen formation, demonstrating cell autonomous defects. Progerin expression in human ECs likewise affected nuclear positioning and flattening and prevented sprouting and lumen formation. Mechanistically, Progerin expression altered LINC complex protein abundance resulting in a failed connection with cytoskeletal Actin and the intermediate filament protein Vimentin. Impairment of the nuclear-cytoskeletal interface was conserved in Progeria patient derived ECs, and partially rescued by inhibiting Progerin with the drug, Progerinin. Taken together, our results reveal that nuclear positioning and flattening is required for angiogenic sprouting and lumen formation respectively and identify the nuclear-cytoskeletal interface as a vulnerability for age-related microvascular dropout and a target for therapeutic intervention.

cell biology↗

RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma

Glioblastoma (GBM), the most frequent and aggressive primary brain tumor, remains refractory to all current therapies including surgical resection, chemotherapy, radiotherapy and immunotherapy. Immunosuppressive mechanisms in the GBM tumor microenvironment contribute to the lack of anti-tumor adaptive immunity. We found that a subset of tumor associated macrophages (TAMs) can be repolarized into an anti-tumor phenotype via agonist stimulation of the retinoic acid-inducible gene I (RIGI), a cytosolic double-stranded RNA pattern recognition receptor (PRR). In silico analysis of adult GBM datasets available in the public domain revealed that RIGI expression by a subset of activated TAMs positively correlated with patient survival. Studies in syngeneic mouse models of GBM showed that intratumoral delivery of stem-loop RNA 14 (SLR14), a RIG-I agonist, improved the efficacy of chemotherapy, radiotherapy and immunotherapy treatments, beyond the effects of other nuclei acid sensor agonists. We found that RIGI+ macrophages are the main drivers of SLR14 effect, combining activation of TAMs and priming of functional cytotoxic CD8+ T lymphocytes and NK cells. The anti-GBM effect of SLR14 is opening a significant new avenue for adult GBM treatment.

cancer biology↗